Kymera Therapeutics CMO Retires; New CMO Appointed

What Happened
Kymera Therapeutics (KYMR) filed a Form 8-K on July 27, 2026 announcing that Chief Medical Officer Jared Gollob, M.D., resigned as CMO for personal reasons effective July 27, 2026. Dr. Gollob will remain with the company as an advisor through December 31, 2026. Terence Rooney, M.D., will succeed Dr. Gollob and serve as CMO effective July 27, 2026. The company furnished a press release under Regulation FD announcing the leadership change.

Key Details

• Filing date: Form 8-K filed July 27, 2026 (Item 5.02 and Item 7.01 disclosure).
• Outgoing CMO: Jared Gollob, M.D.; resignation effective July 27, 2026; will advise until December 31, 2026.
• Incoming CMO: Terence Rooney, M.D.; assumes CMO role effective July 27, 2026.
• Company statement: Dr. Gollob’s resignation was for personal reasons and not due to any disagreement with the company’s practices or policies. A press release was furnished as Exhibit 99.1.

Why It Matters
Executive changes at the C-suite level can affect clinical strategy and investor confidence. This filing signals a planned, immediate leadership transition with continuity provided by Dr. Gollob’s advisory role through year‑end and a publicly disclosed successor, which reduces uncertainty. Retail investors should note the change and watch Kymera’s upcoming clinical and corporate updates for any shifts in medical leadership direction or program priorities.